The global, randomized IDeate-Esophageal01 study will evaluate ifinatamab deruxtecan, a B7-H3–targeted antibody-drug ...

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients ...

Adjuvant nivolumab offered sustained survival benefits in resected esophageal/GEJ cancer post chemoradiation, with PD-L1 ...

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

Malawi holds the highest reported global age-standardized rate for esophageal squamous cell carcinoma (ESCC) incidence and ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

Patients with CSCC who had lymphovascular invasion had a greater incidence of metastasis and disease-specific death than those without.

About 40 percent of cancer cases are considered preventable. Try these lifestyle changes to stay healthy.

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Tevimbra is currently approved in the EU as a treatment for gastric cancer, esophageal squamous cell cancer and small cell ...